Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Top Page
Blueprint Medicines
(NASDAQ:BPMC)
Rating:50Neutral
Price Target:
$128.00
▲(0.04%Upside)
Positive Factors
Acquisition Strategy
Sanofi's announced acquisition of BPMC for $129/share plus CVRs complements Sanofi's existing footprint/portfolio in rare disease and immunology.
Financial Impact
Sanofi expects the acquisition to be immediately accretive to gross margin and accretive to operating income and EPS after 2026.
Market Validation
The transaction validates the opportunity in the indolent systemic mastocytosis market and the value of KIT agents, benefiting both the sector and Blueprint Medicines Corp.
Negative Factors
Competitive Concerns
The timing of the deal may suggest concerns about the quality of upcoming competitor data, motivating the execution of the deal ahead of the data announcement.
Macro Issues
Macro issues affecting biotech, such as pricing and tariffs, remain a concern for investors.
Safety Risks
There remains risk that larger BLU-808 trials will reveal a novel safety issue.
Blueprint Medicines (BPMC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.28B
Dividend YieldN/A
Average Volume (3M)3.77M
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth99.19%
EPS Growth48.43%
CountryUS
Employees682
SectorHealthcare
Sector Strength44
IndustryBiotechnology
Share Statistics
EPS (TTM)0.01
Shares Outstanding64,666,115
10 Day Avg. Volume9,823,759
30 Day Avg. Volume3,774,951
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)5.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.11
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue1.46
Enterprise Value/Gross Profit5.08
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$129.67Price Target Upside1.34% Upside
Rating ConsensusHold
Number of Analyst Covering19
Blueprint Medicines Business Overview & Revenue Model
Company DescriptionBlueprint Medicines Corporation (BPMC) is a precision therapy company focused on developing targeted treatments for genomically defined cancers, rare diseases, and cancer immunotherapy. The company leverages its proprietary scientific platform to create small molecule medicines that selectively target genetic drivers of disease. Blueprint Medicines aims to improve patient outcomes through the development of transformative therapies that address the underlying causes of various diseases.
How the Company Makes MoneyBlueprint Medicines makes money primarily through the development and commercialization of its proprietary drug therapies. The company's revenue model includes product sales, particularly from its FDA-approved therapies like AYVAKIT (avapritinib) and GAVRETO (pralsetinib), which target specific genetic mutations in cancer patients. Additionally, Blueprint Medicines generates revenue through collaborations and licensing agreements with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on sales generated by partner-developed products. Strategic partnerships and collaborations, such as those with Roche and CStone Pharmaceuticals, are significant contributors to its earnings by enhancing its research capabilities and extending its market reach.
Blueprint Medicines Key Performance Indicators (KPIs)
Any
Revenue by Segment
Analyzes revenue from different business segments, highlighting which areas are driving growth and which might need strategic adjustments to enhance profitability.
Analyzes revenue from different business segments, highlighting which areas are driving growth and which might need strategic adjustments to enhance profitability.
Data provided by:
Main Street Data
Main Street DataBlueprint Medicines Earnings Call Summary
Earnings Call Date:May 01, 2025
(Q1-2025)
| % Change Since: 42.96%|
Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment Positive
Despite some challenges in the first quarter and international markets, Blueprint Medicines shows strong performance with significant revenue growth, successful pipeline advancements, and a solid financial position. The sentiment is largely positive, driven by the strong market reception of AYVAKIT and increased revenue guidance.Q1-2025 Updates
Positive Updates
AYVAKIT Revenue Growth
Blueprint Medicines achieved 61% year-over-year AYVAKIT revenue growth, capturing substantial commercial opportunities in systemic mastocytosis.
Raised Revenue Guidance
Due to strong performance and favorable dynamics, Blueprint Medicines raised its AYVAKIT net product revenue guidance to $700 million to $720 million for the year.
Pipeline Advancements
Initiated two proof-of-concept studies for BLU-808 in allergic rhinoconjunctivitis and chronic urticaria. Elenestinib showed potential best-in-disease profile with ongoing pivotal Harbor study.
Strong Cash Position
Blueprint Medicines maintains a strong cash position of $900 million, allowing continued investment in R&D and commercial initiatives.
Positive Market Reception
AYVAKIT has been well-received by both providers and patients, with over 95% of patients expressing high satisfaction, and prescriber base has tripled since ISM approval.
Negative Updates
Challenging First Quarter Dynamics
Typical first quarter insurance dynamics and fewer ordering days impacted gross to net, though this was anticipated and managed.
Limited International ISM Reimbursement
Currently, Germany is the only ex-US market with ISM reimbursement. Other international markets are still in pricing and reimbursement negotiations.
Potential Free Goods Rate Uncertainty
While the free goods rate is currently well below 10%, future Medicare patients' access to commercial therapy could be impacted by foundation funding availability.
Company Guidance
During the Blueprint Medicines 1Q 2025 earnings call, the company reported a 61% year-over-year increase in AYVAKIT revenue, contributing to total revenues of $149.4 million for the quarter. The revenue breakdown included $129.4 million from the U.S. and $20 million from ex-U.S. markets. Due to strong performance and favorable dynamics, Blueprint raised its revenue guidance for the year to a range of $700 million to $720 million. The company highlighted the significant potential of its two prioritized pipeline programs, elenestinib and BLU-808, and their progress in clinical trials, including the initiation of two proof-of-concept studies for BLU-808. Blueprint's strategic focus remains on expanding its prescriber base, particularly among allergists, dermatologists, and gastroenterologists, and increasing patient starts, aiming for a $2 billion revenue goal for AYVAKIT by 2030.Blueprint Medicines Financial Statement Overview
Summary
Blueprint Medicines demonstrates strong revenue growth but remains unprofitable, with significant challenges in cash flow management and operational efficiency. The balance sheet is stable with manageable debt levels, though profitability metrics are concerning.Income Statement
Blueprint Medicines has shown a notable increase in revenue over recent years, indicating strong growth potential with a revenue growth rate of 10.46% TTM. However, the company remains unprofitable with a negative net profit margin of -27.69% and negative EBIT and EBITDA margins, reflecting ongoing challenges in cost management and operational efficiency.40
Negative
Balance Sheet
The company's balance sheet shows a moderate debt-to-equity ratio of 0.36 TTM, indicating manageable debt levels. However, the return on equity remains problematic at -45.51%, reflecting negative profitability. The equity ratio of 28.62% suggests a stable asset base, although the reliance on equity financing could be improved.50
Neutral
Cash Flow
Blueprint Medicines faces challenges with cash flow, as indicated by negative free cash flow and a deteriorating free cash flow growth rate of 23.45% TTM. The operating cash flow to net income ratio is negative, highlighting cash flow pressures and the need for improved cash management strategies.35
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 562.12M | 508.82M | 249.38M | 204.04M | 180.08M | 793.74M | Gross Profit |
| 538.73M | 488.66M | 236.58M | 186.22M | 162.15M | 793.31M | EBIT |
| -174.31M | -212.04M | -486.28M | -549.25M | -648.46M | 302.15M | EBITDA |
| -131.05M | 19.23M | -470.36M | -515.41M | -628.30M | 308.71M | Net Income Common Stockholders |
| -155.73M | -67.09M | -506.98M | -557.52M | -644.09M | 313.88M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 576.24M | 615.49M | 710.64M | 1.08B | 1.03B | 1.55B | Total Assets |
| 1.20B | 1.18B | 1.05B | 1.35B | 1.25B | 1.72B | Total Debt |
| 122.75M | 469.11M | 774.12M | 242.45M | 111.41M | 89.60M | Net Debt |
| 504.00K | 367.09M | 702.84M | 122.74M | -98.54M | -595.03M | Total Liabilities |
| 853.47M | 881.15M | 918.64M | 835.23M | 281.49M | 248.31M | Stockholders Equity |
| 342.13M | 298.67M | 130.61M | 514.68M | 970.74M | 1.47B |
| Cash Flow | Free Cash Flow | ||||
| -150.91M | -197.22M | -452.91M | -511.20M | -559.89M | 383.88M | Operating Cash Flow |
| -145.55M | -192.59M | -436.85M | -502.28M | -298.65M | 387.04M | Investing Cash Flow |
| -59.55M | -47.50M | 274.04M | -149.54M | -225.86M | -434.25M | Financing Cash Flow |
| 215.34M | 273.11M | 119.22M | 561.81M | 50.72M | 617.76M |
Blueprint Medicines Technical Analysis
Positive
127.95
Price Trends
98.02
Positive
98.02
Positive
94.81
Positive
Market Momentum
9.06
Negative
76.12
Negative
99.01
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPMC, the sentiment is Positive. The current price of 127.95 is above the 20-day moving average (MA) of 111.46, above the 50-day MA of 98.02, and above the 200-day MA of 94.81, indicating a bullish trend. The MACD of 9.06 indicates Negative momentum. The RSI at 76.12 is Negative, neither overbought nor oversold. The STOCH value of 99.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BPMC.
Blueprint Medicines Risk Analysis
Blueprint Medicines disclosed 71 risk factors in its most recent earnings report. Blueprint Medicines reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Blueprint Medicines Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $5.12B | 14.86 | 25.71% | ― | -12.31% | -17.53% | |
58 Neutral | $7.61B | ― | 35.68% | ― | -41.71% | -9.37% | |
56 Neutral | $3.84B | 19.61 | -23.61% | ― | 59.15% | -1881.09% | |
55 Neutral | $5.41B | ― | -282.16% | ― | 72.16% | 9.65% | |
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
52 Neutral | $7.82B | ― | -36.68% | ― | -100.00% | 5.49% | |
50 Neutral | $8.28B | ― | -47.71% | ― | 99.19% | 48.43% |
* Healthcare Sector Average
Performance Comparison
BPMC
Blueprint Medicines
127.95
21.56
20.27%
ALKS
Alkermes
31.20
6.39
25.76%
SRPT
Sarepta Therapeutics
37.81
-87.19
-69.75%
AXSM
Axsome Therapeutics
108.08
35.57
49.06%
BBIO
BridgeBio Pharma
39.05
10.05
34.66%
RVMD
Revolution Medicines
40.79
1.05
2.64%
Blueprint Medicines Corporate Events
M&A Transactions
Blueprint Medicines Announces Merger Agreement with Sanofi
Positive
Jun 2, 2025
On June 2, 2025, Blueprint Medicines Corporation entered into a merger agreement with Sanofi, under which Sanofi will acquire Blueprint for approximately $9.1 billion in cash, with additional contingent value rights potentially increasing the total value to $9.5 billion. This acquisition is expected to enhance Sanofi’s portfolio in rare immunological diseases by adding Blueprint’s approved medicine for systemic mastocytosis and its early-stage immunology pipeline, thereby strengthening Sanofi’s position in the immunology sector.
The most recent analyst rating on (BPMC) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Blueprint Medicines stock, see the BPMC Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.